Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Is of American Society of Anesthesiologists (ASA) 1 - 4;~* Is above or equal to the age of 18;~* Scheduled for surgical procedures with a general anesthesia with the use of rocuronium or vecuronium for endotracheal intubation and maintenance of neuromuscular block;~* Scheduled for surgical procedure in supine position;~* Given written informed consent.~Exclusion Criteria:~* Participants in whom a difficult intubation because of anatomical malformations was expected;~* Is known or suspected to have neuromuscular disorders impairing neuromuscular block (NMB) and/or significant renal dysfunction;~* Is known or suspected to have a (family) history of malignant hyperthermia;~* Is known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia;~* Is receiving medication in a dose and/or at a time point known to interfere with neuromuscular blocking agents such as antibiotics, anticonvulsants and Mg2+;~* Participants in whom the use of neostigmine and/or glycopyrrolate may be contraindicated;~* Had already participated in a sugammadex trial;~* Had participated in another clinical trial, not pre-approved by NV Organon, within 30 days of entering into P05960.~* Females who are pregnant:~* Females of childbearing potential not using any method of birth control: condom or using only hormonal contraception as birth control;~* Females who were breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rocuronium + Sugammadex (Type: EXPERIMENTAL): After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
- Rocuronium + Neostigmine (Type: ACTIVE_COMPARATOR): After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered
- Vecuronium + Sugammadex (Type: EXPERIMENTAL): After the last dose of vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
- Vecuronium + Neostigmine (Type: ACTIVE_COMPARATOR): After the last dose of vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered

Based on this trial design, predict the completion outcome and termination type (if applicable).